Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

976 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel human pain insensitivity disorder caused by a point mutation in ZFHX2.
Habib AM, Matsuyama A, Okorokov AL, Santana-Varela S, Bras JT, Aloisi AM, Emery EC, Bogdanov YD, Follenfant M, Gossage SJ, Gras M, Humphrey J, Kolesnikov A, Le Cann K, Li S, Minett MS, Pereira V, Ponsolles C, Sikandar S, Torres JM, Yamaoka K, Zhao J, Komine Y, Yamamori T, Maniatis N, Panov KI, Houlden H, Ramirez JD, Bennett DLH, Marsili L, Bachiocco V, Wood JN, Cox JJ. Habib AM, et al. Among authors: yamaoka k. Brain. 2018 Feb 1;141(2):365-376. doi: 10.1093/brain/awx326. Brain. 2018. PMID: 29253101 Free PMC article.
Spike firing attenuation of serotonin neurons in learned helplessness rats is reversed by ketamine.
Hashimoto K, Yamawaki Y, Yamaoka K, Yoshida T, Okada K, Tan W, Yamasaki M, Matsumoto-Makidono Y, Kubo R, Nakayama H, Kataoka T, Kanematsu T, Watanabe M, Okamoto Y, Morinobu S, Aizawa H, Yamawaki S. Hashimoto K, et al. Among authors: yamaoka k. Brain Commun. 2021 Dec 1;3(4):fcab285. doi: 10.1093/braincomms/fcab285. eCollection 2021. Brain Commun. 2021. PMID: 34939032 Free PMC article.
Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma.
Miura R, Ono A, Yano S, Amioka K, Naruto K, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Nakahara T, Murakami E, Kawaoka T, Miki D, Tsuge M, Hayes CN, Oka S. Miura R, et al. Among authors: yamaoka k. Medicine (Baltimore). 2024 Aug 23;103(34):e39289. doi: 10.1097/MD.0000000000039289. Medicine (Baltimore). 2024. PMID: 39288227 Free PMC article.
Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest Model.
Nakahara H, Ono A, Hayes CN, Shirane Y, Miura R, Fujii Y, Murakami S, Yamaoka K, Bao H, Uchikawa S, Fujino H, Murakami E, Kawaoka T, Miki D, Tsuge M, Oka S; Hiroshima Liver Study Group; TransSCOT Consortium. Nakahara H, et al. Among authors: yamaoka k. JCO Clin Cancer Inform. 2024 Dec;8:e2400108. doi: 10.1200/CCI.24.00108. Epub 2024 Dec 18. JCO Clin Cancer Inform. 2024. PMID: 39693579
Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Miura R, Ono A, Nakahara H, Shirane Y, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Murakami E, Kawaoka T, Miki D, Tsuge M, Kishi T, Ohishi W, Sakamoto N, Arihiro K, Hayes CN, Oka S. Miura R, et al. Among authors: yamaoka k. J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02185-w. Online ahead of print. J Gastroenterol. 2024. PMID: 39652104
Optimal timing of recombinant herpes zoster virus vaccination for a JAK inhibitor treatment in rheumatoid arthritis: a multicentre, open-label, randomised comparative study (STOP-HZ study): study protocol.
Takanashi S, Ohmura K, Misaki K, Ihata A, Matsui T, Tohma S, Saegusa J, Sato S, Matsubara T, Yamaoka K, Amano K, Miyamoto T, Mori Y, Kaneko Y. Takanashi S, et al. Among authors: yamaoka k. BMJ Open. 2024 Nov 17;14(11):e090668. doi: 10.1136/bmjopen-2024-090668. BMJ Open. 2024. PMID: 39551586 Free PMC article.
976 results